SCHEMBL10312089

SCHEMBL10312089

C/C=C/c1cc(Nc2nc(/C=C/c3cccc(F)c3)nc(N3CCNCC3)n2)n[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 6/20 0.47
IDH2 P48735 1/20 0.39
KDR P35968 3/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
PLK4 O00444 3/20 0.36
PAK4 O96013 2/20 0.36
AURKA O14965 3/20 0.36
AURKB Q96GD4 3/20 0.36
JAK2 O60674 3/20 0.36
ABL1 P00519 2/20 0.36
NTRK1 P04629 2/20 0.36
LCK P06239 2/20 0.36
CSF1R P07333 2/20 0.36
RET P07949 2/20 0.36
KIT P10721 2/20 0.36
FGFR1 P11362 2/20 0.36
SRC P12931 2/20 0.36
PDGFRA P16234 2/20 0.36
TYK2 P29597 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312101 0.93 HRH4 (0.48) HRH4IDH2KDRKMT2APLK4
SCHEMBL10312094 0.91 HRH4 (0.59) HRH4KDRKMT2APLK4PAK4
SCHEMBL10312099 0.90 HRH4 (0.46) HRH4KMT2APOLBJAK2NTRK1
SCHEMBL10312144 0.90 HRH4 (0.47) HRH4IDH2KDRKMT2APOLB
SCHEMBL16556869 0.90 AURKA (0.38) HRH4IDH2KDRKMT2APOLB
SCHEMBL10312086 0.89 HRH4 (0.48) HRH4IDH2KDRKMT2APOLB
SCHEMBL10312230 0.89 IDH2 (0.52) HRH4IDH2KDRKMT2APOLB
SCHEMBL10312213 0.88 HRH4 (0.41) HRH4KDRKMT2APLK4PAK4
SCHEMBL10312113 0.88 HRH4 (0.55) HRH4KDRKMT2APLK4PAK4
SCHEMBL10312103 0.88 HRH4 (0.47) HRH4KDRKMT2APLK4PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS STK25, STK35, SGK2 HRH4 2393/4885IDH2 745/4885KDR 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.